Corrigendum to 'Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial'.
Robin von Rotz, Eva M Schindowski, Johannes Jungwirth, Anna Schuldt, Nathalie M. Rieser, Katharina Zahoranszky, Erich Seifritz, Albina Nowak, Peter Nowak, Lutz Jäncke, Katrin H. Preller, Franz X. Vollenweider
EClinicalMedicine February 1, 2023 correction DOI: 10.1016/j.eclinm.2023.101841 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Placebo-controlled Double-blind |
|---|---|
| Population | Adults with major depressive disorder |
| Intervention | Psilocybin |
| Dose | moderate dose |
| Duration | At least two weeks |
| Topics | Depression Psilocybin |
| Keywords | Correction Clinical trials Medical research |
| Citations | 8 |
| Key findings | A single, moderate dose of psilocybin significantly reduces depressive symptoms compared to placebo for at least two weeks. |
Abstract
We wish to provide a correction of the colour representation of Fig. 2 in order to harmonise the colours representing the Psilocybin and the Placebo condition with the corresponding figure caption and with the colour codes from all other figures across the manuscript. Fig. 2 now depicts the Psilocybin condition in blue and the Placebo condition in yellow. The error occurred as a result of an oversight. This change does not affect the results presented in the paper and the figure legend remains unchanged. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trialThese results suggest that a single, moderate dose of psilocybin significantly reduces depressive symptoms compared to a placebo condition for at least two weeks. No serious adverse events were recorded. Larger, multi-centric trials with longer follow-up periods are needed to inform further optimisation of this novel treatment paradigm. Full-Text PDF Open Access